Why the study?
Do direct thrombin inhibitors prevent major venous thromboembolism compared to LMWH or vitamin K antagonists in patients undergoing total hip or knee replacement?
Do direct thrombin inhibitors prevent major venous thromboembolism compared to LMWH or vitamin K antagonists in patients undergoing total hip or knee replacement?
Answers are grounded in this paper and cite their sources.
Direct thrombin inhibitors are as effective as LMWH and vitamin K antagonists for VTE prevention after hip or knee replacement, but are associated with higher mortality and bleeding risks.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Salazar et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: